LGD-4033 and Liothyronine (T3) Interaction
LGD-4033 and Liothyronine (T3) have an interaction requiring monitoring for interaction with 51% confidence. Both LGD-4033 and Liothyronine (T3) can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar). These compounds primarily affect different organ systems.
Compound Profiles
LGD-4033
Selective Androgen Receptor Modulator | Lean Mass
LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.
View full profileLiothyronine (T3)
Thyroid Hormone | Metabolic Optimization
Liothyronine enters target cells via monocarboxylate transporter 8 (MCT8) and other thyroid hormone transporters, then binds to nuclear thyroid hormone receptors (primarily TR-beta in metabolic tissues and TR-alpha in cardiac tissue). The T3-receptor complex forms heterodimers with retinoid X receptors (RXR) and binds to thyroid hormone response elements (TREs) on DNA, directly modulating gene transcription.
View full profileCombined Organ Load
Shared Safety Flags
Frequently Asked Questions
Can I take LGD-4033 with Liothyronine (T3)?
Yes, but with caution. Both LGD-4033 and Liothyronine (T3) can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar). Regular monitoring is advised.
Is LGD-4033 and Liothyronine (T3) safe together?
Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: blood pressure raising. Monitor accordingly.
What are the interactions between LGD-4033 and Liothyronine (T3)?
Both LGD-4033 and Liothyronine (T3) can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar). This assessment has 51% confidence and is inferred from pharmacological mechanism analysis.
How should I time LGD-4033 and Liothyronine (T3)?
LGD-4033 has a half-life of ~24-36 hours and Liothyronine (T3) has a half-life of ~1 day. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.